Evidence map›Paper›PMID 26890118›Full record

ArticleEuropean journal of medicinal chemistry2016

Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.

Andrey E Shchekotikhin, Lyubov G Dezhenkova, Vladimir B Tsvetkov, Yuri N Luzikov, Yulia L Volodina, Victor V Tatarskiy, Anastasia A Kalinina, Michael I Treshalin, Helen M Treshalina, Vladimir I Romanenko and 6 more

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Andrey E ShchekotikhinGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia; Mendeleyev University of Chemical Technology, 9 Miusskaya Square, Moscow 125190, Russia. Electronic address: shchekotikhin@mail.ru.
Lyubov G DezhenkovaGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Vladimir B TsvetkovTopchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, 29 Leninsky Avenue, 119991 Moscow, Russia; Institute for Physical-Chemical Medicine, 1A M. Pirogovskaya Street, Moscow 119435, Russia.
Yuri N LuzikovGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Yulia L VolodinaFederal State Budgetary Scientific Institution «N.N. Blokhin Cancer Research Center» of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Victor V TatarskiyFederal State Budgetary Scientific Institution «N.N. Blokhin Cancer Research Center» of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Anastasia A KalininaFederal State Budgetary Scientific Institution «N.N. Blokhin Cancer Research Center» of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Michael I TreshalinGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Helen M TreshalinaFederal State Budgetary Scientific Institution «N.N. Blokhin Cancer Research Center» of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Vladimir I RomanenkoFederal State Budgetary Scientific Institution «N.N. Blokhin Cancer Research Center» of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Dmitry N KaluzhnyEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilov Street, Moscow 119991, Russia.
Michael KubbutatProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany.
Dominique ScholsRega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Yves PommierDevelopmental Therapeutics Branch, National Cancer Institute, NIH, 37 Convent Drive, 37-5068, Bethesda, MD 20892, USA.
Alexander A ShtilGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia; Federal State Budgetary Scientific Institution «N.N. Blokhin Cancer Research Center» of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.
Maria N PreobrazhenskayaGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Russian Cancer Research Center NN Blokhin · RUGause Institute of New Antibiotics Russian Academy of Medical Sciences · RUD. Mendeleyev University of Chemical Technology of Russia · RUEngelhardt Institute of Molecular Biology · RUNational Cancer Institute · USRega Institute for Medical Research · BERussian Academy of Sciences · RU

Funding

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer DrugsZIABC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 2009 to 2025
$23.0M
DNA Topoisomerases as Target of Action of Anticancer DrugsZIABC006161 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 2009 to 2025
$16.8M
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITIONZ01BC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Intramural NIH HHS Z01 BC006150
6 · The paper itself

Abstract

Anthraquinones and their analogues, in particular heteroarene-fused anthracendiones, are prospective scaffolds for new compounds with improved antitumor characteristics. We herein report the use of a 'scaffold hopping' approach for the replacement of the core structure in the previously discovered hit compound naphtho[2,3-f]indole-5,10-dione 2 with an alternative anthra[2,3-b]furan-5,10-dione scaffold. Among 13 newly synthesized derivatives the majority of 4,11-dihydroxy-2-methyl-5,10-dioxoanthra[2,3-b]furan-3-carboxamides demonstrated a high antiproliferative potency against a panel of wild type and drug resistant tumor cell lines, a property superior over the reference drug doxorubicin or lead naphtho[2,3-f]indole-5,10-dione 2. At low micromolar concentrations the selected derivative of (R)-3-aminopyrrolidine 3c and its stereoisomer (S)-3-aminopyrrolidine 3d caused an apoptotic cell death preceded by an arrest in the G2/M phase. Studies of intracellular targets showed that 3c and 3d formed stable intercalative complexes with the duplex DNA as determined by spectral analysis and molecular docking. Both 3c and 3d attenuated topoisomerase 1 and 2 mediated unwinding of the supercoiled DNA via a mechanism different from conventional DNA-enzyme tertiary complex formation. Furthermore, 3d decreased the activity of selected human protein kinases in vitro, indicating multiple targeting by the new chemotype. Finally, 3d demonstrated an antitumor activity in a model of murine intraperitoneally transplanted P388 leukemia, achieving the increase of animal life span up to 262% at tolerable doses. Altogether, the 'scaffold hopping' demonstrated its productivity for obtaining new perspective antitumor drug candidates.

Indexed as

AnimalsAnthracenesAntineoplastic AgentsCell Line, TumorDrug Resistance, MultipleDrug Resistance, NeoplasmDrug Screening Assays, AntitumorFuransHumansLeukemiaMiceNeoplasmsProtein Kinase InhibitorsStructure-Activity RelationshipTopoisomerase InhibitorsAnthracenesAntineoplastic AgentsFuransProtein Kinase InhibitorsTopoisomerase InhibitorsAnthra[2,3-b]furan-3-carboxamidesAntitumor activityCircumvention of multidrug resistanceCytotoxicityDNA ligandsProtein kinase inhibitorsTopoisomerase inhibitors

Identifiers

PMID26890118
PMCPMC7832087
OpenAlexW2297509256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.